Michael Kahn
Overview
Explore the profile of Michael Kahn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
6322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Page M, Katz J, Darville R, Gabriel G, Ladha K, Huang A, et al.
Reg Anesth Pain Med
. 2024 Jul;
PMID: 39084703
Introduction: The Transitional Pain Service (TPS) is an innovative, personalized approach to postsurgical opioid consumption and pain management. The objectives of this study were to identify trajectories of opioid consumption...
2.
Zhou Y, He Z, Li T, Choppavarapu L, Hu X, Cao R, et al.
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927910
The therapeutic potential of targeting the β-catenin/CBP interaction has been demonstrated in a variety of preclinical tumor models with a small molecule inhibitor, ICG-001, characterized as a β-catenin/CBP antagonist. Despite...
3.
Gutova M, Hibbard J, Ma E, Natri H, Adhikarla V, Chimge N, et al.
Front Immunol
. 2024 Mar;
15:1342625.
PMID: 38449858
Introduction: Despite aggressive standard-of-care therapy, including surgery, radiation, and chemotherapy, glioblastoma recurrence is almost inevitable and uniformly lethal. Activation of glioma-intrinsic Wnt/β-catenin signaling is associated with a poor prognosis and...
4.
Kim W, Buckley A, Lee D, Hiroto A, Nenninger C, Olson A, et al.
Nat Commun
. 2024 Feb;
15(1):1231.
PMID: 38336745
Androgen deprivation therapy (ADT) targeting androgen/androgen receptor (AR)- signaling pathways is the main therapy for advanced prostate cancer (PCa). However, ADT eventually fails in most patients who consequently develop castration-resistant...
5.
Zhou Y, Li T, He Z, Choppavarapu L, Hu X, Cao R, et al.
bioRxiv
. 2023 Nov;
PMID: 38013997
The therapeutic potential of targeting the β-catenin/CBP interaction has been demonstrated in a variety of preclinical tumor models with a small molecule inhibitor, ICG-001, characterized as a β-catenin/CBP antagonist. Despite...
6.
Tran H, Ai A, Gallardo-Huizar O, Kahn M, Mathisen G
Heliyon
. 2023 Oct;
9(9):e19616.
PMID: 37809561
A 66-year-old male with a history of low back pain was found to have discitis and osteomyelitis. Biopsy and PCR testing revealed infection. This bacteria does not typically cause disease,...
7.
Chimge N, Chen M, Nguyen C, Zhao Y, Wu X, Gonzalez P, et al.
Curr Mol Pharmacol
. 2023 Sep;
17(1):e060923220758.
PMID: 37691195
Background And Objective: Disease relapse and therapy resistance remain serious impediments to treating cancer. Leukemia stem cells (LSC) are therapy resistant and the cause of relapse. A state of deep...
8.
Lee C, Pratap K, Zhang L, Chen H, Gautam S, Arnaoutova I, et al.
Biochim Biophys Acta Mol Basis Dis
. 2023 Sep;
1870(1):166874.
PMID: 37666439
Glycogen storage disease type Ia (GSD-Ia) is caused by a deficiency in the enzyme glucose-6-phosphatase-α (G6Pase-α or G6PC) that is expressed primarily in the gluconeogenic organs, namely liver, kidney cortex,...
9.
Poku E, Ono M, Higuchi Y, Chea J, Melendez E, Teo J, et al.
Curr Mol Pharmacol
. 2023 Aug;
17(1):e170823219875.
PMID: 37594155
Introduction: Our previous work has demonstrated significant effects on the oxidative stress response, mitochondrial function, and oxidative phosphorylation in the livers and intestines of p300 S89A knockin (S89AKI) mice. We...
10.
Higuchi Y, Nguyen C, Chimge N, Ouyang C, Teo J, Kahn M
Curr Mol Pharmacol
. 2023 May;
17(1):e290523217409.
PMID: 37254542
Background And Objective: The first clinically evaluated CBP/β-catenin antagonist, PRI-724, displayed an excellent safety profile administered intravenously via continuous infusion. Eisai recently disclosed a third-generation, orally available, reportedly CBP/β-catenin antagonist,...